Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03729869 · ClinicalTrials.gov registry record · Phase 2

Impact of Progesterone on Stress Reactivity and Cannabis Use

A Phase 2 study of Cannabis Use, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
148
Enrollment target
1
Study location

NCT03729869: Completed Phase 2 study of Cannabis Use, sponsored by Medical University of South Carolina.

NCT03729869 is a Phase 2 study of Cannabis Use that has completed, run by Medical University of South Carolina. The registered enrollment target is 148 participants, below the 276-participant average among 44 other Cannabis Use trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03729869, a Phase 2 study of Cannabis Use, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
148 participants
Enrollment target
1
Study location

Study Summary

This is a research study to find out if a hormone called progesterone affects marijuana users' stress response and marijuana use. Progesterone is a naturally occurring sex hormone involved in the menstrual cycle and reproduction, and has been shown to reduce withdrawal symptoms when people stop using substances like cocaine and nicotine. It is not FDA approved for treating cannabis users and is considered an investigational drug in this study.

Primary Outcome

Subjects will rate marijuana craving on a 0-7 Likert scale where 0 is Not at All and 7 is extremely.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Progesterone

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2019-01-18
Est. Completion 2022-11-09
Phase Phase 2

What the finished NCT03729869 record still lists

NCT03729869 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 276-participant average among 44 other Cannabis Use trials with a reported enrollment target (46% lower).

The record links to 1 condition, with Cannabis Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03729869 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT03729869 about?

NCT03729869 is a clinical study titled "Impact of Progesterone on Stress Reactivity and Cannabis Use". This is a research study to find out if a hormone called progesterone affects marijuana users' stress response and marijuana use. Progesterone is a naturally occurring sex hormone involved in the menstrual cycle and reproduction, and has been shown to reduce withdrawal symptoms when people stop usin...

What is the current status of trial NCT03729869?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2019-01-18. Estimated completion is 2022-11-09.

What conditions does trial NCT03729869 study?

This clinical trial studies the following conditions: Cannabis Use.

What interventions are being tested in trial NCT03729869?

The interventions under investigation include: Placebo (DRUG), Progesterone (DRUG).

Who is sponsoring clinical trial NCT03729869?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03729869 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cannabis Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03729869's enrollment target sits among peer trials

148 16th of 44 higher than 29 of 44 other Cannabis Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cannabis Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00739362 · 148 participants · Phase 2

    Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

  • NCT03161223 · 148 participants · Phase 1

    Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

  • NCT03858231 · 148 participants · Phase 4

    Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery

  • NCT04486352 · 148 participants · Phase 1

    A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03729869, the US trial registry maintained by the National Library of Medicine. NCT03729869 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.